Macquarie Group
ZYNE

Macquarie Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Macquarie Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,900
Closed -$6K – 2129
2018
Q4 		$6K Buy
+1,900
New +$10.4K ﹤0.01% 2072
2018
Q1 		– Sell
-2,600
Closed -$33K – 2428
2017
Q4 		$33K Buy
+2,600
New +$29.8K ﹤0.01% 2084

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Macquarie Group's ZYNE Position: Q1 2019 in Review

Macquarie Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2019, closing a stake of 1,900 shares — an estimated $6K sold.

Macquarie Group first reported a position in ZYNE in Q4 2017 and held it in 2 quarters. The position peaked at $33K in Q4 2017. 61 funds tracked by Wall St. Rank hold ZYNE as of Q1 2019.

  • Macquarie Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 1,900 Zynerba Pharmaceuticals, Inc shares in Q1 2019, an estimated $6K.
  • Macquarie Group first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 2 quarters.
  • Macquarie Group's Zynerba Pharmaceuticals, Inc position peaked at $33K in Q4 2017.
  • 61 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.